Literature DB >> 32464348

Expanding the cerebrovascular phenotype of the p.R258H variant in ACTA2 related hereditary thoracic aortic disease (HTAD).

Birgitte Rode Diness1, Rachel Nina Palmquist2, Rikke Norling3, Hanne Hove4, Henning Bundgaard5, Jens Michael Hertz6, Daniel Kondziella7, Derk Krieger8, Morten Dunø2, Sabine Grønborg4.   

Abstract

Heterozygous variants in smooth muscle alpha-actin gene (ACTA2) are the most frequent cause of autosomal dominant hereditary thoracic aortic disease (HTAD). Several genotype-phenotype associations have been described, including a severe multisystemic smooth muscle disorder associated with de novo ACTA2 p.R179 variants, characterized by highly penetrant and early onset vascular disease, involvement of smooth muscle cell (SMC)-dependent organs and a distinct cerebrovascular phenotype. Missense variants at position 258 (p.R258C and p.R258H) have also been reported to have a more severe presentation including an increased risk for aortic dissection and a high risk of stroke. It has previously been suggested that the cerebrovascular phenotype of patients with p.R258 variants could represent a mild presentation of the cerebrovascular phenotype associated with p.R179 variants. Here we report on a five generation HTAD family with the p.R258H variant and describe the cerebrovascular findings seen in three family members, to expand on the previously reported phenotype associated with variants at this codon.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ACTA2; Arteriopathy; HTAD

Mesh:

Substances:

Year:  2020        PMID: 32464348     DOI: 10.1016/j.jns.2020.116897

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  1 in total

1.  Expanding ACTA2 genotypes with corresponding phenotypes overlapping with smooth muscle dysfunction syndrome.

Authors:  Anita Kaw; Kaveeta Kaw; Ellen M Hostetler; Ana Beleza-Meireles; Adam Smith-Collins; Catherine Armstrong; Ingrid Scurr; Timothy Cotts; Rajani Aatre; Michael J Bamshad; Dawn Earl; Abraham Groner; Katherine Agre; Yehuda Raveh; Callie S Kwartler; Dianna M Milewicz
Journal:  Am J Med Genet A       Date:  2022-05-14       Impact factor: 2.578

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.